Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases

Details for Australian Patent Application No. 2005229496 (hide)

Owner Merck Patent GmbH

Inventors Lang, Florian

Agent Davies Collison Cave

Pub. Number AU-A-2005229496

PCT Pub. Number WO2005/094829

Priority 04005761.4 11.03.04 EP

Filing date 8 February 2005

Wipo publication date 13 October 2005

International Classifications

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 31/165 (2006.01) - having aromatic rings, e.g. colchicine, atenolol, progabide

Event Publications

2 November 2006 PCT application entered the National Phase

  PCT publication WO2005/094829 Priority application(s): WO2005/094829

2 September 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005229497-Methods for interfering with fibrosis

2005229493-Treatment of impaired respiratory function with gaboxadol